Downregulation of circ-YES1 Suppresses NSCLC Migration and Proliferation Through The miR-142-3p–HMGB1 Axis

Yongbin Chi

Gongli Hospital

Yan Wang

Gongli Hospital

Dawei Zhou

Baoshan District Integrative Medicine Hospital

Wanchao Liu

Baoshan District Integrative Medicine Hospital

Ruodong Han

People's Hospital of Bozhou

Mingming Jin (✉ asdjinmingming@126.com)

Shanghai Gongli Hospital <https://orcid.org/0000-0003-3574-2410>

Primary research

Keywords: non-small cell lung cancer, circ-YES1, miR-142-3p, high mobility group protein B1, proliferation, migration

Posted Date: October 13th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-88834/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background: Circular RNAs (circRNAs) are a new family of abundant regulatory RNAs with roles in various types of cancer. While the hsa_circ_0046701 (circ-YES1) function in non-small cell lung cancer (NSCLC) is unclear.

Methods: Circ-YES1 expression in normal pulmonary epithelial and NSCLC cells was examined. The small interfering RNA for circ-YES1 was prepared, cell proliferation and migration were assessed. Tumorigenesis in nude mice was assayed to validate the role of circ-YES1. Bioinformatics analyses and luciferase reporter assays were utilized to identify downstream targets of circ-YES1.

Results: Compared to normal pulmonary epithelial cells, the circ-YES1 expression increased in NSCLC cells, and cell proliferation and migration were suppressed after circ-YES1 knockdown. Both high mobility group protein B1 (HMGB1) and miR-142-3p were found to be downstream targets of circ-YES1, and miR-142-3p inhibition and HMGB1 overexpression reversed the effects of circ-YES1 knockdown on cell proliferation and migration. Similarly, HMGB1 overexpression reversed the miR-142-3p overexpression effects on these two processes. The imaging experiment results revealed that circ-YES1 knockdown impeded tumor development and metastasis in a nude mouse xenograft model.

Conclusion: Taken together, our results show that circ-YES1 promotes tumor development through the miR-142-3p–HMGB1 axis and support the development of circ-YES1 as a new therapeutic NSCLC target.

Background

Lung cancer is an extremely common and fatal malignancy worldwide. Presently, the lung cancer 5-year survival rate is < 15%¹. More than four-fifths of all lung cancers are characterized as non-small cell lung cancer (NSCLC), which is the most common subtype. Unfortunately, NSCLC is often diagnosed in advanced stages of the trait^{1,2}. As such, further studies are needed to improve our understanding of NSCLC in order to identify new therapeutic targets and diagnostic biomarkers.

Circular RNAs (circRNAs) are novel and abundant non-coding RNAs that are highly stable due to their covalent closed-loop structure³. In general, the expression of circRNAs is species-, tissue-, and cell-specific^{4,5}. The majority of circRNAs are < 1,500 nucleotides in length, with an average length of ~ 500 nucleotides^{6,7}. Several circRNAs have been reported to associate with the recurrence and prognosis of NSCLC^{8–10}. For instance, circ-0014130 has been reported to participate in cell proliferation and apoptosis via the miR-142-5p–IGF-1 axis in NSCLC¹¹, whereas hsa_circ_0002483 has been demonstrated to impede tumor progression and enhance the sensitivity of cells to Taxol by targeting miR-182-5p¹². In yet another *in vitro* and *in vivo* study, hsa_circ_0046701 (circ-YES1) was significantly up-regulated in glioma, and circ-YES1 knockdown was found to inhibit cell invasion and proliferation¹³. Here, we report abnormal circ-YES1 expression in NSCLC and examine the circ-YES1 roles in NSCLC progression and development.

Materials & Methods

Ethics statement

We procured four-week-old BALB/c nude mice weighing 15~20 g from SLARC (Shanghai, China). Pudong New Area Gongli Hospital Ethics Committee approved animal experiments.

Cell culture

We purchased human pulmonary epithelial cells (BEAS-2B) and NSCLC cells (H1650, A549, and PC-9) from American Type Culture Collection (Manassas, VA, USA). We cultured cells in RPMI-1640 medium (Gibco, Grand Island, NY, USA) supplemented with 10% (v/v) fetal bovine serum (FBS) in humidified atmosphere of 5% CO₂ at 37°C.

Cell proliferation and clone formation assays

We assessed cell proliferation through Cell Counting Kit-8 (CCK-8) assay (Invitrogen, Carlsbad, CA, USA). Differently-treated cells (2×10^3 /well) were added in triplicate to wells of 96-well plates and cultured for 0, 24, 48, 72, and 96 h. We examined cell proliferation after each time point. Colony formation was assessed in differently-treated cells (2×10^3 /well) cultured in Dulbecco's modified Eagle media supplemented with 10% (v/v) FBS in wells of 6-well plates for 10 d. Colonies were fixed, stained, counted, and photographed.

Cell migration assays

We performed cell migration assays in Transwell chambers (membrane pore size, 8 µm; BD Biosciences, Franklin Lakes, NJ, USA) housed within 24-well plates. We added differently-treated cells (1×10^5 /unit) in 200 µL of serum-free media to upper chamber. We filled lower chamber with 500 µL of complete media, which served as the chemoattractant. Cells that had migrated through membrane pores after 1 d were fixed with 4% (w/v) paraformaldehyde for 0.5 h and stained with Crystal violet for 10 min.

Amplification of target genes by quantitative polymerase chain reactions (qPCR)

We extracted total RNA with TRIzol reagent (Invitrogen), and synthesized cDNA through the pTRUEscript First Strand cDNA Synthesis kit (Aidlab, Beijing, China). To amplify target genes, quantitative polymerase chain reactions (qPCR) were carried out in the presence of gene-specific primers and 2× SYBR Green qPCR Mix (Invitrogen) in an ABI 7900HT Fast Real-Time PCR system (Thermo Fisher Scientific, Waltham, MA, USA). The primers were as follows: 5'-GAAATTGGTGAAACAC-3' (forward) and 5'-GCTTCATAATCATATAAGGC-3' (reverse) for circ-YES1; 5'-GTCGTATCCAGTGCAGGG-3' (forward) and 5'-CGACGTGTAGTGTTCCTA-3' (reverse) for miR-142-3p; 5'-AGGCTGACAAGGCTCGTTATG-3' (forward) and 5'-TGTCATCCGCAGCAGTGTTG-3' (reverse) for high mobility group protein B1 (HMGB1); 5'-CTCGCTTCGGCAGCACA-3' (forward) and 5'-AACGCTTCATTTGCGT-3' (reverse) for U6; and 5'-AATCCCATCACCATCTTCC-3' (forward) and 5'-CATCACGCCACAGTTTCC-3' (reverse) for GAPDH. The miR-142-3p primer for the reverse transcription reaction was 5'-

GTCGTATCCAGTGCAGGGTCCGAGGTATTTCGCACTGGATACGA CTCCATAAA-3'. We calculated fold-change in expression by $2^{-\Delta\Delta CT}$ method. The expression levels of circ-YES1 and HMGB1 were normalized to that of GAPDH, whereas we normalized the miR-142-3p expression level to that of U6.

Tumor xenograft formation and metastasis assays

H1650 cells (5×10^6) transfected with circ-YES1 siRNA or negative control (NC) siRNA were injected into BALB/c nude mice ($n = 6$) right flank. We measured tumors every five days using vernier calipers, and calculated the tumor volume as $= 0.5 \times \text{length} \times \text{width}^2$. Mice were euthanized after 30 d, and tumor specimens were used in Ki-67 immunohistochemistry experiments.

H1650 cells (2×10^5) transfected with HMGB1 expression or empty plasmids were intravenously injected into the tails of mice. Metastasis was assessed after 1 month by intravenously injecting luciferin (150 mg/kg body weight) and imaging the whole body.

Dual luciferase reporter assays

We prepared reporter plasmids through inserting circ-YES1 or the 3' untranslated region (UTR) of HMGB1 into the pmirGLO vector (Promega, Madison, WI, USA). Subsequently, reporter plasmids were individually cotransfected with miR-142-3p inhibitor into human embryonic kidney (HEK) 239T cells with Lipofectamine 2000 transfection reagent. After 2 d of incubation, firefly and Renilla luciferase activity was measured with Dual Luciferase Reporter Assay system (Promega), following manufacturer's instructions.

Statistical analyses

We reported data as means $\pm$ SD. We utilized GraphPad Prism software (GraphPad, San Diego, CA, USA) to compare differences between groups. We regarded P -values < 0.05 statistically significant.

Results

Circ-YES1 expression is increased in NSCLC cells and circ-YES1 knockdown suppresses cell proliferation and migration

The hsa_circ_0046701 (circ-YES1) expression level was higher in H1650 and A549 cells than that in BEAS-2B cells (Figure 1A); therefore, all subsequent experiments were performed in H1650 and A549 cells. In bioinformatics analysis, hsa_circ_0046701 was found to be located on chromosome chr18:745707-751804, and hsa_circ_0046701 was derived from exon 4 of the *YES1* gene, with a length of 453 bp. Therefore, hsa_circ_0046701 was designated as circ-YES1 (Figure 1B). In qPCR analysis, the circ-YES1 level was significantly lower in both H1650 and A549 cells than that in BEAS-2B cells (Figure 1C). Furthermore, circ-YES1 knockdown suppressed cell proliferation as observed in CCK-8 (Figure 1D, E) and clone formation (Figure 1F, G) assays. In addition, circ-YES1 knockdown reduced the migration of H1650 and A549 cells (Figure 1H, I), indicating that circ-YES1 has an important role in this process.

HMGB1 and miR-142-3p are circ-YES1 downstream targets, and miR-142-3p inhibition and HMGB1 overexpression can reverse the circ-YES1 knockdown effects on cell proliferation and migration

Bioinformatics analysis revealed that miR-142-3p was circ-YES1 downstream target, which prompted us to generate wild-type (WT) and mutant miR-142-3p luciferase reporter plasmids (Figure 2A). We found that luciferase activity decreased after cotransfection with WT circ-YES1 and miR-142-3p inhibitor (Figure 2B), inferring that circ-YES1 directly interacts with miR-142-3p. Bioinformatics analysis also revealed that HMGB1 was miR-142-3p downstream target (Figure 2C), and the results of luciferase reporter assays confirmed that miR-142-3p binds to the HMGB1 3' UTR (Figure 2D).

We transfected H1650 and A549 cells with circ-YES1 siRNA, miR-142-3p inhibitor, or the HMGB1-overexpressing plasmid alone or in combination. The results of qPCR advised that circ-YES1 was successfully silenced. Furthermore, circ-YES1 knockdown decreased the miR-142-3p expression level, and HMGB1 overexpression cannot recover the HMGB1 expression (Figure 3A), indicating that miR-142-3p and HMGB1 are downstream targets of circ-YES1. Furthermore, circ-YES1 knockdown increased the miR-142-3p expression level, and the miR-142-3p inhibitor could not down-regulate miR-142-3p, even after circ-YES1 knockdown. Similarly, HMGB1 overexpression could not down-regulate miR-142-3p, even after circ-YES1 knockdown (Figure 3B), indicating that HMGB1 is a miR-142-3p downstream target. Circ-YES1 knockdown decreased the HMGB1 expression level; however, decreased miR-142-3p expression partially rescued HMGB1 expression (Figure 3C), confirming that HMGB1 was a miR-142-3p downstream target.

In clone formation analysis, circ-YES1 knockdown inhibited the proliferation of both H1650 and A549 cells. Interestingly, miR-142-3p knockdown and HMGB1 overexpression could reverse the circ-YES1 knockdown effects on proliferation (Figure 3D, E) and migration (Figure 3F, G) in both cell types.

HMGB1 overexpression can restore cell proliferation and migration after miR-142-3p overexpression

The relationship between HMGB1 and miR-142-3p was further examined. In qPCR analysis, miR-142-3p expression increased significantly after the miR-142-3p inhibitor transfection. HMGB1 overexpression could not down-regulate miR-142-3p (Figure 4A), although miR-142-3p overexpression could down-regulate HMGB1. As the heterogenic HMGB1 mRNA is reported to lack a 3' UTR, miR-142-3p cannot affect the HMGB1 mRNA level, which explains why HMGB1 expression was increased after HMGB1 overexpression, even after miR-142-3p overexpression (Figure 4B). In clone formation analysis, HMGB1 overexpression up-regulated the miR-142-3p level and rescued the proliferation of both cell types (Figure 4C, D). Furthermore, miR-142-3p overexpression inhibited cell migration, although HMGB1 overexpression could reverse the miR-142-3p overexpression effects (Figure 4E, F), indicating that HMGB1 can restore the proliferation and migration of H1650 and A549 cells .

Knockdown of circ-YES1 suppresses tumor development and metastasis in a nude mouse xenograft model

A lentiviral vector was used to deliver sh-circ-YES1 or sh-negative control into H1650 cells, which were subsequently injected into nude mice to induce tumor development. Tumors were measured 5 days after grafting. Compared to the control, circ-YES1 knockdown reduced the xenograft volume and weight (Figure 5A–C). The immunohistochemistry experiment results revealed decrease in the Ki67 signal, consistent with the inhibition of tumor growth by circ-YES1 knockdown (Figure 5D). In qPCR analysis, the miR-142-3p level was higher in tumors of mice injected with circ-YES1 siRNA than that in mice injected with negative control siRNA (Figure 5E); however, the HMGB1 level was lower (Figure 5F). Imaging of the whole body of mice showed that circ-YES1 knockdown inhibited tumor development and metastasis (Figure 5G).

Discussion

The development of NSCLC involves the tumor suppressor gene inactivations and the tumor promoter gene activations (i.e., oncogenes). In the past few decades, several advancements have been made in the early diagnosis and treatment of NSCLC; however, these breakthroughs have not translated into significant improvements in the prognosis of the disease¹⁴. CircRNAs have important roles in the regulation of several types of cancer¹⁵, and elevated levels of circRNAs have been reported to associate with the clinical manifestations of NSCLC, which include tumor occurrence, stage, and distant metastasis^{16,17}. Here, we report increased circ-YES1 expression in NSCLC. In addition, circ-YES1 knockdown inhibited cell proliferation and migration, and HMGB1 and miR-142-3p were circ-YES1 downstream targets.

CircRNAs can regulate various cellular processes through miRNAs¹⁸. We discovered that miR-142-3p was a circ-YES1 downstream target. The results of luciferase reporter assays validated the interaction between circ-YES1 and miR-142-3p. Interestingly, a previous study has demonstrated that miR-142-3p could reduce the cancer stem cell phenotypes and the radio-resistance of breast cancer cells¹⁹. In colorectal cancer, miR-142-3p expression suppressed cell growth through targeting CDK4²⁰, indicating that miR-142-3p is a tumor suppressor^{21,22}. In this study, circ-YES1 knockdown increased the miR-142-3p expression level, whereas miR-142-3p inhibition reversed the circ-YES1 knockdown effects on cell migration and proliferation, consistent with the miR-142-3p overexpression experiment results, in which cell migration and proliferation were found to be inhibited.

Here, we report that HMGB1 was a miR-142-3p downstream target. HMGB1, a component protein of chromatin found in all nucleated mammalian cells, was initially discovered in the calf thymus in 1973²³. Subsequently, Wang and colleagues demonstrated a role for HMGB1 in sepsis²⁴, although it has also been reported to participate in the transcriptional regulation of cancer-related genes such as tumor necrosis factor alpha, E-selectin, breast cancer type 1 susceptibility protein, and insulin receptor²⁵. HMGB1 overexpression is correlated to poor prognosis of many cancer²⁶, and HMGB1 is highly expressed in NSCLC cells and tissues²⁷. Here, circ-YES1 knockdown and miR-142-3p overexpression decreased HMGB1 expression. Furthermore, HMGB1 or miR-142-3p overexpression reversed the circ-YES1

knockdown effects on cell proliferation and migration, indicating that circ-YES1 can inhibit these processes by regulating the miR-142-3p–HMGB1 axis.

Circ-YES1 promotes oncogenesis by functioning as an miR-142-3p sponge. Therefore, targeting the circ-YES1–miR-142-3p–HMGB1 axis represents a new approach in the treatment of NSCLC, and our results support the application of circ-YES1 as a new prognostic marker in this disease.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and materials

All data generated or analysed during this study are included in this published article.

Competing interests

No competing interests are declared.

Funding

We thank the National Natural Science Foundation of China (Grant No. 82003142) for supporting this research.

Authors' contributions

Mingming Jin, Wanchao Liu, Ruodong Han conducted the study design. Yongbin Chi carried out the assays and collected the samples. Yan Wang performed the statistical analysis. Dawei Zhou participated the coordination of research and worked as technical consultants. Mingming Jin drafted the manuscript. All authors reviewed and approved the final manuscript.

Acknowledgements

None.

References

1. Qin H, Wang F, Liu H, et al. New advances in immunotherapy for non-small cell lung cancer. *Am J Transl Res*. 2018;10:2234–45.

2. Szejniuk WM, Robles AI, McCulloch T, Falkmer UGI, Roe OD. Epigenetic predictive biomarkers for response or outcome to platinum-based chemotherapy in non-small cell lung cancer, current state-of-art. *Pharmacogenomics J.* 2019;19:5–14.
3. Xu XW, Zheng BA, Hu ZM, et al. Circular RNA hsa_circ_000984 promotes colon cancer growth and metastasis by sponging miR-106b. *Oncotarget.* 2017;8:91674–83.
4. Xu T, Wu J, Han P, Zhao Z, Song X. Circular RNA expression profiles and features in human tissues: a study using RNA-seq data. *BMC Genom.* 2017;18:680.
5. Quan G, Li J. Circular RNAs: biogenesis, expression and their potential roles in reproduction. *J Ovarian Res.* 2018;11:9.
6. Lyu D, Huang S. The emerging role and clinical implication of human exonic circular RNA. *RNA Biol.* 2017;14:1000–6.
7. Zheng Q, Bao C, Guo W, et al. Circular RNA profiling reveals an abundant circHIPK3 that regulates cell growth by sponging multiple miRNAs. *Nat Commun.* 2016;7:11215.
8. Zhao D, Liu H, Zhang X, et al. Downregulated expression of hsa_circ_0037515 and hsa_circ_0037516 as novel biomarkers for non-small cell lung cancer. *Am J Transl Res.* 2020;12:162–70.
9. Wang Y, Xu R, Zhang D, et al. Circ-ZKSCAN1 regulates FAM83A expression and inactivates MAPK signaling by targeting miR-330-5p to promote non-small cell lung cancer progression. *Transl Lung Cancer Res.* 2019;8:862–75.
10. She Y, Han Y, Zhou G, Jia F, Yang T, Shen Z. hsa_circ_0062389 promotes the progression of non-small cell lung cancer by sponging miR-103a-3p to mediate CCNE1 expression. *Cancer Genet.* 2020;241:12–9.
11. Wang M, Shi J, Jiang H, Xu K, Huang Z. Circ_0014130 Participates in the Proliferation and Apoptosis of Nonsmall Cell Lung Cancer Cells via the miR-142-5p/IGF-1 Axis. *Cancer Biother Radiopharm.* 2020;35:233–40.
12. Li X, Yang B, Ren H, et al. Hsa_circ_0002483 inhibited the progression and enhanced the Taxol sensitivity of non-small cell lung cancer by targeting miR-182-5p. *Cell Death Dis.* 2019;10:953.
13. Li G, Yang H, Han K, Zhu D, Lun P, Zhao Y. A novel circular RNA, hsa_circ_0046701, promotes carcinogenesis by increasing the expression of miR-142-3p target ITGB8 in glioma. *Biochem Biophys Res Commun.* 2018;498:254–61.
14. Chen Y, Wang T, Wang W, et al. Prognostic and clinicopathological significance of SIRT1 expression in NSCLC: a meta-analysis. *Oncotarget.* 2017;8:62537–44.
15. Li L, Wan K, Xiong L, Liang S, Tou F, Guo S. CircRNA hsa_circ_0087862 Acts as an Oncogene in Non-Small Cell Lung Cancer by Targeting miR-1253/RAB3D Axis. *Onco Targets Ther.* 2020;13:2873–86.
16. Ding HX, Lv Z, Yuan Y, Xu Q. The expression of circRNAs as a promising biomarker in the diagnosis and prognosis of human cancers: a systematic review and meta-analysis. *Oncotarget.* 2018;9:11824–36.

17. Bachmayr-Heyda A, Reiner AT, Auer K, et al. Correlation of circular RNA abundance with proliferation—exemplified with colorectal and ovarian cancer, idiopathic lung fibrosis, and normal human tissues. *Sci Rep*. 2015;5:8057.
18. Zhang SJ, Ma J, Wu JC, Hao ZZ, Zhang YN, Zhang YJ. CircRNA EPB41L2 inhibits tumorigenicity of lung adenocarcinoma through regulating CDH4 by miR-211-5p. *Eur Rev Med Pharmacol Sci*. 2020;24:3749–60.
19. Troschel FM, Bohly N, Borrmann K, et al. miR-142-3p attenuates breast cancer stem cell characteristics and decreases radioresistance in vitro. *Tumour Biol*. 2018;40:1010428318791887.
20. Zhu X, Ma SP, Yang D, et al. miR-142-3p Suppresses Cell Growth by Targeting CDK4 in Colorectal Cancer. *Cell Physiol Biochem*. 2018;51:1969–81.
21. Zhu K, Zhang Z, Zhang H, Wang Z, Wang F. MiR-142-3p targeting NUCKS1 inhibits proliferation and invasion of pancreatic cancer cells. *Artif Cells Nanomed Biotechnol*. 2020;48:415–24.
22. Xu T, He BS, Pan B, et al. MiR-142-3p functions as a tumor suppressor by targeting RAC1/PAK1 pathway in breast cancer. *J Cell Physiol*. 2020;235:4928–40.
23. Goodwin GH, Johns EW. Isolation and characterisation of two calf-thymus chromatin non-histone proteins with high contents of acidic and basic amino acids. *Eur J Biochem*. 1973;40:215–9.
24. Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. *Science*. 1999;285:248–51.
25. Thanos D, Maniatis T. The high mobility group protein HMG I(Y) is required for NF-kappa B-dependent virus induction of the human IFN-beta gene. *Cell*. 1992;71:777–89.
26. Wu T, Zhang W, Yang G, et al. HMGB1 overexpression as a prognostic factor for survival in cancer: a meta-analysis and systematic review. *Oncotarget*. 2016;7:50417–27.
27. Tu L, Long X, Song W, et al. MiR-34c acts as a tumor suppressor in non-small cell lung cancer by inducing endoplasmic reticulum stress through targeting HMGB1. *Onco Targets Ther*. 2019;12:5729–39.

Figures

Figure 1

Expression of circ-YES1 was increased in NSCLC cells and circ-YES1 knockdown inhibited cell proliferation and migration. (A) Expression of circ-YES1 in H1650, PC-9, A549, and HEAS-2B cells by qPCR. Data are presented as means $\pm$ SD. ***, $P < 0.001$ vs. HEAS-2B. (B) Genomic loci of the YES1 gene and circ-YES1. The black arrow indicates back-splicing. (C) Expression of circ-YES1 after transfection of cells with circ-YES1 siRNA (si-circ-YES1) or negative control siRNA (NC). Data are presented as means $\pm$ SD. ***, $P < 0.001$ vs. NC. (D and E) H1650 (D) and A549 (E) cell proliferation as assessed by CKK-8 assays. Data are presented as means $\pm$ SD. ***, $P < 0.001$ vs. NC. (F and G) H1650 and A549 cell proliferation as assessed by clone formation assays. Data are presented as means $\pm$ SD. ***, $P < 0.001$ vs. NC. (H and I) H1650 and A549 cell migration as assessed by Transwell assays. Data are presented as means $\pm$ SD. ***, $P < 0.001$ vs. NC.

Figure 2

HMGB1 and miR-142-3p are downstream targets of circ-YES1. (A) The binding sites of miR-142-3p in circ-YES1 are shown. The mutated circ-YES1 is also shown. (B) Relative luciferase activity was measured 48 h after transfection of HEK293T cells with miR-142-3p mimic/negative control (NC) or circ-YES1 wild type (wild)/mutant (Mut). Data are presented as means $\pm$ SD. ***, $P < 0.001$. (C) The binding sites of miR-142-3p with the 3' UTR of circ-YES1 are shown. The mutated 3' UTR of circ-YES1 is also shown. (D) Relative luciferase activity was measured 48 h after transfection of HEK293T cells with miR-142-3p mimic/NC or 3' UTR-circ-YES1 wild/Mut. Data are presented as means $\pm$ SD. ***, $P < 0.001$.

Figure 3

MiR-142-3p knockdown and HMGB1 overexpression reversed the effects of circ-YES1 knockdown on the proliferation and migration of H1650 and A549 cells. (A–C) Expression of circ-YES1 (A), miR-142-3p (B), and HMGB1 (C) by qPCR. Data are presented as means $\pm$ SD. *, $P < 0.05$; ***, $P < 0.001$ vs NC; ###, $P < 0.001$ vs si-circ-YES1. (D and E) H1650 and A549 cell proliferation as assessed by clone formation assays. Data are presented as means $\pm$ SD. ***, $P < 0.001$ vs. NC; ###, $P < 0.001$ vs si-circ-YES1. (F and G) H1650 and A549 cell migration as assessed by Transwell assays. Data are presented as means $\pm$ SD. ***, $P < 0.001$ vs. NC; ###, $P < 0.001$ vs si-circ-YES1.

Figure 4

HMGB1 overexpression reversed the effects of miR-142-3p overexpression on the proliferation and migration of H1650 and A549 cells. (A and B) Expression of miR-142-3p (A) and HMGB1 (B) by qPCR. Data are presented as means $\pm$ SD. ***, $P < 0.001$ vs NC; ###, $P < 0.001$ vs inhibitor. (C and D) H1650 and A549 cell proliferation as assessed by clone formation assays. Data are presented as means $\pm$ SD. ***, $P < 0.001$ vs. NC; ###, $P < 0.001$ vs mimic. (E and F) H1650 and A549 cell migration as assessed by Transwell assays. Data are presented as means $\pm$ SD. ***, $P < 0.001$ vs. NC; ###, $P < 0.001$ vs inhibitor.

Figure 5

Circ-YES1 knockdown impedes tumor development and metastasis in a nude mouse xenograft model. (A) Representative images of nude mouse xenografts after injection of H1650 cells. (B) Tumors were measured every 5 days. Data are presented as means $\pm$ SD. ***, $P < 0.001$ vs. NC. (C) Tumor weight was measured 30 d after grafting. Data are presented as means $\pm$ SD. ***, $P < 0.001$ vs. NC. (D) Immunohistochemical staining of Ki-67 in tumor specimens from both sh-NC and sh-circRNA groups. (E and F) Expression of miR-142-3p (E) and HMGB1 (F) by qPCR. Data are presented as means $\pm$ SD. ***, $P < 0.001$ vs. NC. (G) Whole-body images of mice showing tumor development and metastasis 5 weeks after injection of H1650 cells.